Pharmaxis Ltd (AU:SNT) has released an update.
Pharmaxis Ltd’s lead drug SNT-5505 is advancing into Phase 1b/2 clinical trials at Heidelberg University to treat high-risk blood cancers, with A$2.5 million funding from German Cancer Aid. The trial aims to improve treatment for myelodysplastic syndrome and chronic myelomonocytic leukemia, addressing a significant unmet medical need in a market worth approximately US$6 billion. This development follows successful pre-clinical research and complements an ongoing Australian study for lower-risk patients.
For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.
